Show simple item record

dc.contributor.authorRockman, S
dc.contributor.authorLowther, S
dc.contributor.authorCamuglia, S
dc.contributor.authorVandenberg, K
dc.contributor.authorTaylor, S
dc.contributor.authorFabri, L
dc.contributor.authorMiescher, S
dc.contributor.authorPearse, M
dc.contributor.authorMiddleton, D
dc.contributor.authorKent, SJ
dc.contributor.authorMaher, D
dc.date.accessioned2021-02-04T00:36:18Z
dc.date.available2021-02-04T00:36:18Z
dc.date.issued2017-05-01
dc.identifierpii: S2352-3964(17)30153-6
dc.identifier.citationRockman, S., Lowther, S., Camuglia, S., Vandenberg, K., Taylor, S., Fabri, L., Miescher, S., Pearse, M., Middleton, D., Kent, S. J. & Maher, D. (2017). Intravenous Immunoglobulin Protects Against Severe Pandemic Influenza Infection. EBIOMEDICINE, 19, pp.119-127. https://doi.org/10.1016/j.ebiom.2017.04.010.
dc.identifier.issn2352-3964
dc.identifier.urihttp://hdl.handle.net/11343/259144
dc.description.abstractInfluenza is a highly contagious, acute, febrile respiratory infection that can have fatal consequences particularly in individuals with chronic illnesses. Sporadic reports suggest that intravenous immunoglobulin (IVIg) may be efficacious in the influenza setting. We investigated the potential of human IVIg to ameliorate influenza infection in ferrets exposed to either the pandemic H1N1/09 virus (pH1N1) or highly pathogenic avian influenza (H5N1). IVIg administered at the time of influenza virus exposure led to a significant reduction in lung viral load following pH1N1 challenge. In the lethal H5N1 model, the majority of animals given IVIg survived challenge in a dose dependent manner. Protection was also afforded by purified F(ab')2 but not Fc fragments derived from IVIg, supporting a specific antibody-mediated mechanism of protection. We conclude that pre-pandemic IVIg can modulate serious influenza infection-associated mortality and morbidity. IVIg could be useful prophylactically in the event of a pandemic to protect vulnerable population groups and in the critical care setting as a first stage intervention.
dc.languageEnglish
dc.publisherELSEVIER SCIENCE BV
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0
dc.titleIntravenous Immunoglobulin Protects Against Severe Pandemic Influenza Infection
dc.typeJournal Article
dc.identifier.doi10.1016/j.ebiom.2017.04.010
melbourne.affiliation.departmentMicrobiology and Immunology
melbourne.affiliation.departmentBio21
melbourne.affiliation.facultyMedicine, Dentistry & Health Sciences
melbourne.affiliation.facultyAffiliate
melbourne.source.titleEBioMedicine
melbourne.source.volume19
melbourne.source.pages119-127
dc.rights.licenseCC BY-NC-ND
melbourne.elementsid1201097
melbourne.contributor.authorKent, Stephen
melbourne.contributor.authorFabri, Louis
melbourne.contributor.authorRockman, Steven
dc.identifier.eissn2352-3964
melbourne.accessrightsOpen Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record